REDWOOD
CITY, Calif., Feb. 2, 2023
/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology
company reimagining cell therapy through the development of
innovative immunotherapies for patients with cancer and other
incurable diseases, today announced the company's participation in
the following investor conferences:
- Guggenheim Oncology Conference 2023
Fireside chat on Thursday, February 9,
2023, at 11:20 a.m. ET
- SVB Securities Global Biopharma Conference (Virtual)
Fireside chat on Thursday, February 16,
2023, at 3:00 p.m. ET
A live webcast of these discussions will be accessible from
Arcellx's website at www.arcellx.com in the Investors section.
A replay of the webcasts will be archived and available for 30 days
following the event.
About Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company
reimagining cell therapy by engineering innovative immunotherapies
for patients with cancer and other incurable diseases. Arcellx
believes that cell therapies are one of the forward pillars of
medicine and Arcellx's mission is to advance humanity by developing
cell therapies that are safer, more effective, and more broadly
accessible. Arcellx's lead product candidate, CART-ddBCMA, is being
developed for the treatment of relapsed or refractory multiple
myeloma (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been
granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced
Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T
therapy, ARC-SparX, through two programs: a Phase 1 study of
ACLX-001 for r/r MM, initiated in the second quarter of 2022; and
ACLX-002 in relapsed or refractory acute myeloid leukemia and
high-risk myelodysplastic syndrome, initiated in the fourth quarter
of 2022. For more information on Arcellx, please visit
www.arcellx.com. Follow Arcellx on Twitter (@arcellx) and
LinkedIn.
Arcellx, Inc. Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements in this press release that are not purely
historical are forward-looking statements, including Arcellx's
expectations regarding the timing of clinical trials for its
product candidates. The forward-looking statements contained
herein are based upon Arcellx's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. These forward-looking statements are neither promises
nor guarantees and are subject to a variety of risks and
uncertainties, including those set forth in the section entitled
Part II, Item 1A (Risk Factors) in the Quarterly Report on Form
10-Q for the period ended September 30,
2022, filed with the Securities and Exchange Commission
(SEC) on November 14, 2022, and other
documents that Arcellx files from time to time with the SEC. These
forward-looking statements are made as of the date of this press
release, and Arcellx assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Investors:
Myesha Lacy
ir@arcellx.com 510-418-2412
Media:
Andrea Cohen Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163
View original content to download
multimedia:https://www.prnewswire.com/news-releases/arcellx-to-participate-in-upcoming-investor-conferences-301737203.html
SOURCE Arcellx, Inc.